Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

BetterLife Pharma Inc C.BETR

Alternate Symbol(s):  BETRF

Healthcare
BetterLife Pharma Inc. is a biopharmaceutical company. The Company is focused on developing and commercializing two compounds, BETR-001 and BETR-002, to treat neuro-psychiatric and neurological disorders. BETR-001 is a non-hallucinogenic Lysergic Acid Diethylamide (LSD) derivative. BETR-001 mimics the projected therapeutic properties of LSD without causing its undesirable side effects such as hallucinations and cardiac toxicity. BETR-001 is a therapy to treat debilitating psychiatric disorders with high unmet need, such as major depressive disorder and anxiety disorders; as well as neurological disorders such as neuropathic pain. BETR-002 is a formulation of a derivative of dihydrohonokiol, a known anti-anxiety compound for treatment of benzodiazepine dependency, anxiety and spasticity. The Company also owns a drug candidate for the treatment of viral infections such as COVID-19. The Company’s subsidiaries include MedMelior Inc., BetterLife Pharma US Inc. and Blife Therapeutics Inc.


CSE:BETR - Post by User

BetterLife Pharma Inc > Why the silence regarding the Halt?
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(3)
•••
Post by mattusvion Dec 07, 2020 8:32pm
130 Views
Post# 32055175

Why the silence regarding the Halt?

Why the silence regarding the Halt?

BETR OW and perplexed >>>

Stock was Halted? And not a peep from anyone from BetterLife?

The silence is deafening … Come on guys… we shareholders deserve better treatment then this.

Tony Pullen?

Investor Relations Contact Dost Mushtaq ?

Ahmad Doroudian, PhD Chief Executive Officer & Director?

Hooshmand Sheshbaradaran, PhD Chief Operating Officer?

Angela Ogden, MD Chief Medical Officer ?

Moira Ong, CPA, CA Chief Financial Officer ?

Jeff Fellows(1) Head of Regulatory ?

What gives?


<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities